EUVIMEDEUVIMED entdecken
Crossref

Prognosis of patients with acute lymphoblastic leukaemia relapsing after allogeneic stem cell transplantation

Christelle Ferra Coll iD, Mireia Morgades de la Fe iD, Laura Prieto García iD, Carlos Pinho Vaz iD, María Inmaculada Heras Fernando iD, Rebeca Bailen Almorox iD, Irene Garcia-Cadenas iD, Marisa Calabuig Muñoz iD, Teresa Zudaire Ripa iD, Joud Zanabili Al-Sibai iD, Sandra Novoa iD, Beatriz Aguado iD und 7 weitere

European Journal of Haematology · 2023-06 · 110 (6) · 659-668

DOI: 10.1111/ejh.13947 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Haematology, online erschienen am 18.03.2023. Verfasst von Christelle Ferra Coll und 18 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Hematology Department, Institut Català d'Oncologia, Institut de Recerca contra la Leucemia Josep Carreras, Hospital Germans Trias i Pujol. B…. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Precursor Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The outcomes of patients with acute lymphoblastic leukaemia (ALL) presenting relapse after allogeneic stem cell transplant (allo‐SCT) are poor, with few data available in this setting. Objective and Methods To evaluate the outcomes of patients with ALL presenting relapsed after allo‐SCT, we performed a retrospective study including 132 from 11 centres in Spain.

Results

Therapeutic strategies consisted of palliative treatment ( n = 22), chemotherapy ( n = 82), tyrosine kinase inhibitors ( n = 26), immunotherapy with inotuzumab and/or blinatumumab ( n = 19), donor lymphocyte infusions ( n = 29 pts), second allo‐SCT ( n = 37) and CAR T therapy ( n = 14). The probability of overall survival (OS) at 1 and 5 years after relapse was 44% (95% confidence interval [CI]: 36%; 52%) and 19% (95% CI: 11%; 27%). In the 37 patients undergoing a second allo‐SCT, the 5‐year estimated OS probability was 40% [22%; 58%]. Younger age, recent allo‐SCT, late relapse, 1st complete remission at 1st allo‐SCT and chronic graft‐versus‐host disease confirmed their positive impact on survival in the multivariable analysis.

Conclusion

Despite the poor prognosis of patients with ALL presenting relapse after a first allo‐SCT, some can be satisfactorily rescued and a second allo‐SCT still remains a valid option for selected patients. Moreover, emerging therapies really might improve ALL patients outcome when relapsing after an allo‐SCT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationPrecursor Cell Lymphoblastic Leukemia-LymphomaHumansRetrospective StudiesTransplantation, HomologousNeoplasm Recurrence, LocalStem Cell TransplantationPrognosisAcute DiseaseRecurrence

Stichwörter der Autor:innen

acute lymphoblastic leukaemiaallogeneic haematopoietic stem cell transplantrelapse

Autor:innen und Institutionen

  • Clinical Hematology Department, Institut Català d'Oncologia, Institut de Recerca contra la Leucemia Josep Carreras, Hospital Germans Trias i Pujol. Badalona, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Universitat de Vic, Universitat Central de Catalunya, Catalunya, Spain.
  • Hematology Department, Hospital Universitario de Salamanca, IBSAL (Instituto Biosanitario de Salamanca), Salamanca, Spain.
  • Marrow Transplant Department, Instituto Português de Oncologia, Porto, Portugal.
  • Hematology Department, Hospital General Universitario Morales Meseguer, Murcia, Spain.
  • Hematology Department Hospital General Universitario Gregorio Marañon, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.

ORCID-Profile: Christelle Ferra Coll, Mireia Morgades de la Fe, Laura Prieto García, Carlos Pinho Vaz, María Inmaculada Heras Fernando, Rebeca Bailen Almorox, Irene Garcia-Cadenas, Marisa Calabuig Muñoz, Teresa Zudaire Ripa, Joud Zanabili Al-Sibai, Sandra Novoa, Beatriz Aguado, Anna Torrent Catarineu, Oriana López-Godino, Rodrigo Martino Bofarull, Mi Kwon, Antonio Campos Júnior, Dolores Caballero Barrigón, Josep-Maria Ribera Santasusana

Zitieren

APA

Ferra Coll, C., Morgades de la Fe, M., Prieto García, L., Vaz, C. P., Heras Fernando, M. I., Bailen Almorox, R., Garcia-Cadenas, I., Calabuig Muñoz, M., Ripa, T. Z., Zanabili Al-Sibai, J., Novoa, S., Aguado, B., Torrent Catarineu, A., López-Godino, O., Martino Bofarull, R., Kwon, M., Campos Júnior, A., Caballero Barrigón, D., & Ribera Santasusana, J. M. (2023). Prognosis of patients with acute lymphoblastic leukaemia relapsing after allogeneic stem cell transplantation. European Journal of Haematology, 110(6), 659-668. https://doi.org/10.1111/ejh.13947

Vancouver

Ferra Coll C, Morgades de la Fe M, Prieto García L, Vaz CP, Heras Fernando MI, Bailen Almorox R, et al. Prognosis of patients with acute lymphoblastic leukaemia relapsing after allogeneic stem cell transplantation. European Journal of Haematology. 2023;110(6):659-668. doi:10.1111/ejh.13947

BibTeX
@article{FerraColl2023,
  author = {Ferra Coll, Christelle and Morgades de la Fe, Mireia and Prieto García, Laura and Vaz, Carlos Pinho and Heras Fernando, María Inmaculada and Bailen Almorox, Rebeca and Garcia-Cadenas, Irene and Calabuig Muñoz, Marisa and Ripa, Teresa Zudaire and Zanabili Al-Sibai, Joud and Novoa, Sandra and Aguado, Beatriz and Torrent Catarineu, Anna and López-Godino, Oriana and Martino Bofarull, Rodrigo and Kwon, Mi and Campos Júnior, Antonio and Caballero Barrigón, Dolores and Ribera Santasusana, Josep-Maria},
  title = {Prognosis of patients with acute lymphoblastic leukaemia relapsing after allogeneic stem cell transplantation},
  journal = {European Journal of Haematology},
  year = {2023},
  volume = {110},
  number = {6},
  pages = {659--668},
  doi = {10.1111/ejh.13947}
}
Kostenlos starten →